ImageneBio (IMA)
NASDAQ:IMA
Want to see IMA full AI Analyst Report?
IMA Stock Chart & Stats
$5.90
--
Market closed
$5.90
--
Day’s Range― - ―
52-Week Range$3.94 - $18.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$65.07M
Enterprise Value-$1.58M
Total Cash (Recent Filing)$117.21M
Total Debt (Recent Filing)$8.15M
Price to Earnings (P/E)―
Beta0.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,279,130
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.03
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$13.00Price Target Upside120.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low leverage and sizeable assets give the company financial flexibility to support clinical programs without heavy interest burdens. This balance-sheet strength helps preserve operational optionality and supports R&D continuity over the coming quarters despite burn.
$30M Private Financing Improves LiquidityThe announced private warrant financing is a material structural capital raise that meaningfully bolsters near-term cash resources. That funding reduces immediate runway pressure and increases the firm's ability to execute planned late‑phase development and expansion activities.
Pipeline Expansion And Late‑phase FocusManagement is directing capital toward advancing late‑phase work in atopic dermatitis and broadening IMG‑007 into alopecia areata. Pursuing multiple indications diversifies clinical risk and enlarges the long‑term addressable market if trials are successful.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow around -$52.1M TTM demonstrates material cash burn. The magnitude requires recurring external funding to sustain development, increasing the risk of disrupted timelines or tougher financing terms if market access tightens.
Pre-commercial With Minimal RevenueThe company remains pre‑commercial with no trailing revenue, making enterprise value fully dependent on clinical outcomes. Multi‑year revenue decline underscores limited current commercialization capability and heightens sensitivity to trial setbacks and funding cycles.
Dilution And Financing-related RisksThe pre‑funded warrant structure creates potential share issuance and contingent obligations (registration penalties). Reliance on such financings increases dilution risk and may erode existing equity over time if additional capital raises are required to sustain development.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.94 and its highest was $18.00 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $65.07M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Undervalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 11,279,130 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
-35.20%
Trailing 12-Months
Asset Growth
4.47%
Trailing 12-Months
Company Description
ImageneBio
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
IMA Stock 12 Month Forecast
Average Price Target
$13.00
▲(120.34% Upside)
Technical Analysis
Ownership Overview
31.09% Insiders
3.60% Mutual Funds
39.73% Other Institutional Investors
22.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---